|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
24 March 2025 |
|
Main ID: |
NCT05670821 |
|
Date of registration:
|
02/01/2023 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms
|
|
Scientific title:
|
Post-marketing Surveillance of Spesolimab I.V. Infusion in Improvement of Generalized Pustular Psoriasis (GPP) With Acute Symptoms in Japan |
|
Date of first enrolment:
|
April 18, 2023 |
|
Target sample size:
|
52 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
https://clinicaltrials.gov/ct2/show/NCT05670821 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- GPP patients with acute symptoms who are administered Spesolimab Intravenous (I.V.)
Infusion in Japan
- Patients who have never been treated with Spesolimab I.V. Infusion before enrolment
Exclusion Criteria:
- None
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Generalized Pustular Psoriasis
|
|
Intervention(s)
|
|
Drug: Spesolimab
|
|
Primary Outcome(s)
|
|
Incidence of adverse drug reactions (ADRs)
[Time Frame: Up to 36 weeks]
|
|
Secondary ID(s)
|
|
1368-0093
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|